A targeted multi-stage nano-therapeutic to modulate immunotherapy | 5310
Translational Medicine

Translational Medicine
Open Access

ISSN: 2161-1025

+44 1223 790975

A targeted multi-stage nano-therapeutic to modulate immunotherapy

4th International Conference on Translational Medicine

October 26-28, 2015 Baltimore, USA

Asad Moten

Harvard University, USA

Posters-Accepted Abstracts: Transl Med

Abstract :

Cancer vaccine often suffers from poor clinical efficacy due to the nature of antigen, vaccine formulation and unfavorable tumor microenvironment. Here we report the development of a porous silicon micro-particle (PSM)-based nano-vaccine that induces tumor stromal changes and strong anti-tumor immunity in treating HER2 positive breast cancer. This HER2 nano-vaccine elicited substantially increased intra-tumor MHCII expression, induced abundant CD11c+ cell infiltration, and produced robust antitumor immunity against established HER2 positive mammary gland tumors in a CD8+ T cell-dependent manner. It also inhibited spontaneous tumor development in Balb-neuT transgenic mice. Using ovalbumin (OVA) as a model antigen, we found that the nano vector-delivered OVA was preferentially enriched into early endosome and presented to T cells in a TAP-dependent fashion. Consequently, it elicited much stronger CD8+ T cell responses than soluble OVA. Taken together, PSM delivery of vaccination provided an effective approach for producing strong anti-tumor immunity by promoting innate immune cell infiltration and transforming the tumor tissue from an otherwise immunosuppressive to an immuno stimulating micro-environment.

Biography :